Hims & Hers Health Issues Q2 Revenue Guidance of $680M-$700M
HIMS has more than doubled off its 52-week low of $13.74.
Summary
Hims & Hers Health, Inc. has issued its revenue guidance for the second quarter, projecting sales to be in the range of $680 million to $700 million. This specific forward-looking financial guidance is highly material for traders, as it provides a direct indication of the company's expected performance and will be immediately incorporated into valuation models. While the headline does not provide context on analyst consensus, the release of this guidance is a key data point for assessing the company's growth trajectory. Investors will now compare this range against existing expectations to determine the potential impact on the stock. This guidance is a significant update following the company's last 10-K, which reported strong revenue growth for fiscal year 2025.
At the time of this announcement, HIMS was trading at $28.06 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $13.74 to $70.43. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.